BHC News and Press, Bausch Health Companies Inc.

2024-06-20 18:11:15 ET More on Bausch Health Companies Why Bausch Health Stock Plunged After Posting First Quarter 2024 Results Bausch Health Companies (BHC) Q1 2024 Earnings Call Transcript Bausch Health Companies Inc. 2024 Q1 - Results - Earnings Call Presentation ...

LAVAL, QC / ACCESSWIRE / June 20, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health" or the "Company") and its gastroenterology business, Salix Pharmaceuticals, today announced that it has filed a patent infringement lawsuit in the U.S. District Court for the District of Ne...

2024-06-20 02:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-06-17 21:24:55 ET Summary Paulson's 13F portfolio value increased to ~$1.45B with 18 securities, top positions include Madrigal Pharma and Bausch Health. John Paulson is known for his leveraged bets against the real-estate bubble, and converted to a Family Office structure in...

LAVAL, QC / ACCESSWIRE / June 14, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global diversified pharmaceutical company enriching lives through a relentless drive to deliver better health outcomes, recently presented at two global healthcare conferences. Bausch Health's gastroente...

2024-06-09 10:44:45 ET Summary Carl Icahn's 13F filing shows 14 holdings, including Icahn Enterprises, CVR Energy, Southwest Gas Holdings, Occidental Petroleum warrants, and Bausch Health. Icahn established a new stake in JetBlue Airways this quarter. Also, a significant position ...

LAVAL, QC / ACCESSWIRE / May 23, 2024 / Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), today announced additional Canadian public drug plan listings for Pr UCERIS ® (budesonide) aerosol foam to treat mild to moderate distal ulcerative colitis in ad...

2024-05-22 16:31:48 ET Summary Bausch + Lomb, a spin-off from Bausch Health, has shown solid performance with revenues of $4.1bn in 2023 and a narrowing net loss of $(260m). The company's Q1 2024 report shows growth in all segments, including Vision Care, Surgical, and Pharmaceuti...

LAVAL, QC / ACCESSWIRE / May 17, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals, today announced that they will be presenting data from its Phase 2 trial evaluating Amiselimod as treatment for active ulcerative colitis (UC). ...

LAVAL, QC / ACCESSWIRE / May 15, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced the results of its 2024 annual meeting of shareholders. Annual Meeting Results The 10 directors nominated at the Company's 2024 annual meeting of shareholders held on May 14, 2024, were e...